US-listed companies
Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals, Inc.HEPA

Market cap

$2.94M

P/E ratio

Income statement Balance sheet Cash flow

	Jun 30, 2014	Jun 30, 2015	Jun 30, 2016	Jun 30, 2017	Dec 31, 2018	Dec 31, 2019	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022
Cash	2	5	7	13	3	14	41	91	51
Prepaid expenses	164,421	681,249	491,045	210,174	135,591	465,693	2	6	5
Total current assets	2	5	8	13	3	14	43	97	56
Property and equipment, net	14,526	81,441	80,848	67,564	32,434	57,166	108,440	152,772	81,620
Right-of-use assets	-	-	-	-	-	797,913	556,492	0	0
In-process research and development	-	-	3	3	3	3	3	3	3
Goodwill	-	-	2	2	2	2	2	2	-
Other assets	4,200	51,344	69,955	63,182	127,794	127,939	285,098	583,326	426,174
Total assets	2	5	13	18	8	20	49	104	60
Accounts payable	243,896	1	4	2	748,428	491,557	4	2	3
Accrued expenses	207,915	456,722	820,894	1	661,421	493,636	659,572	3	5
Operating Lease, Liability, Current	-	-	-	-	-	266,696	279,826	0	0
Short-term portion of contingent consideration	-	-	-	-	-	-	-	3	0
Total current liabilities	458,739	2	5	3	3	1	5	8	8
Contingent consideration, non-current	-	-	3	3	3	2	3	2	2
Deferred tax liability	-	-	-	-	-	18,752	409,022	409,022	409,022
Operating Lease, Liability, Noncurrent	-	-	-	-	-	540,751	0	0	-
Total liabilities	5	2	12	9	6	4	8	11	10
Series A	-	13	13	1	855,808	855,808	855,808	855,808	855,808
Series C	-	-	-	-	930,311	861,033	856,320	845,320	840,320
Common Stock, Value, Issued	1,848	2,228	3,224	7,571	1,661	375	3,203	7,623	7,623
Additional paid-in capital	2	17	32	68	77	98	143	225	224
Accumulated other comprehensive loss	-	-	-	-	-	-	-	-	-90,168
Accumulated deficit	-5,421,337	-27,613,857	-44,612,495	-59,503,545	-76,463,932	-83,185,630	-104	-133	-176
Series A	-	13	13	1	855,808	855,808	855,808	855,808	855,808
Series C	-	-	-	-	930,311	861,033	856,320	845,320	840,320
Total stockholders equity	-2,933,180	3	1	9	2	16	41	93	50
Total liabilities and stockholders’ equity	2	5	13	18	8	20	49	104	60